King's College Hospital NHS Foundation Trust, London, UK
Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
Gut. 2024 Jul 11;73(8):1235-1268. doi: 10.1136/gutjnl-2023-331695.
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
全球范围内，大多数癌症的死亡率正在下降，但在英国和其他西方国家，肝癌（HCC）的发病率和死亡率却在上升。HCC 是一种高度致命的癌症，通常诊断较晚，发病率与死亡率之比接近 1。尽管有许多治疗选择，包括那些与良好的中长期生存相关的治疗选择，但英国 HCC 的 5 年生存率仍低于 20%。性别、种族和贫困是影响 HCC 发病率和/或生存率的重要人口统计学因素。这些临床实践指南将为 HCC 患者的评估和管理提供循证建议。我们提出的建议所依据的临床和科学数据都有详细的总结。大部分内容都具有广泛的相关性，但治疗算法是基于英国可用的疗法，并获得了在国民保健制度中使用的监管批准。
